Insulin oral - Oramed Pharmaceuticals

Drug Profile

Insulin oral - Oramed Pharmaceuticals

Alternative Names: Orally ingestible insulin capsule; ORMD-0801

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator Oramed Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 01 Nov 2016 Oramed and Integrium plan a phase IIa trial for Type-2 diabetes mellitus in USA (PO) (NCT02954601)
  • 01 Oct 2016 Oramed initiates enrolment in a phase II trial for Type-2 diabetes mellitus in USA (NCT02954601)
  • 28 Jul 2016 Interim adverse events data from a phase IIb trial in Type-2 diabetes mellitus released by Oramed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top